Marker Therapeutics Inc (MRKR)

[Phantom Lord]

Nothing new which was to be expected. Just gave a recap of data we've already seen and reaffirmed the company's financial position. As of the latest release they are still on track to release lymphoma data within the next three months. Hopefully they don't release in Q2 earnings and try to pass it off as "1st half of the year" like they've done in the past.

The only real takeaways here are that Vera is still speaking highly of the lymphoma trial as we are nearing data and they have been in discussions with other pharma companies for a potential partnership. Vera's confidence has not seemed to waver and he is most certainly privy to all the data that we should be getting soon. I would have expected him to tone that down a bit if the data was looking shaky. Obviously, he could just be talking the trial up knowing that giving any hint of failure wouldn't look good but In my conversations with him in the past I don't get this vibe from him. Take that as you will. Like I've said in the past any partnership will require more data. Vera all but confirmed that in the presentation yesterday when asked about potential partnerships. Said they have talked to some other companies but they want to see more data to essentially "de-risk" any investment or partnership. Makes sense and is nothing we didn't already assume.

The lymphoma data that is coming soon seems to be the only thing we have to look forward to for a while. If data impresses the company should be able to have their path forward mapped out by the end of the year but I'm not expecting much else news this year other than that data and them initiating the MT-401 OTS trial which I don't expect to bring much interest until data starts to roll in most likely mid next year at the earliest. He mentioned the grant for the pancreatic trial as well but they don't have anything confirmed right now. If the pancreatic trial moves forward it will be with non-dilutive funding and will not effect the company's current cash runway. I will say, it is nice to see the company finally start taking their finances seriously.

All this being said if the lymphoma data is good it should warrant enough interest to at the very least keep the share price stable. We'll find out in roughly three months.